Detection of Biased Agonist Activation

• US 20100273185A1
• Filed: 04/27/2010
• Published: 10/28/2010
• Est. Priority Date: 04/27/2009
• Status: Abandoned Application

• Current Assignee: X-Body Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Sru Biosystems Incorporated
• Inventors: Fernandez, Rafael, Getman, Michael, Sandberg, Eric
• Application Number:
  US12/768,269
• Publication Number:
  US 20100273185A1
• Time in Patent Office: Days
• US Class Current: 435/7.200
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/54373 involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
• CPC Class Codes: G01N 33/557 using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction

Abstract

The invention provides single assay methods to detect the activity of biased agonists or agonists that are less than full agonists on cells.

Claims

1. A method of determining if a ligand or stimulus is a biased agonist comprising:

a) immobilizing or placing one or more cells on a surface of a colorimetric resonant reflectance optical biosensor;

b) applying a ligand or stimulus to the one or more cells;

c) detecting colorimetric resonant reflectance optical peak wavelength values (PWVs) for the one or more cells over time; and

d) comparing the PWVs of step (c) to PWVs over time of a full agonist acting on the same or similar one or more cells of step (a);

wherein, the ligand or stimulus is a biased agonist if the PWVs of the ligand or stimulus over time are smaller in magnitude or later in onset or both than the PWVs over time of the full agonist.

2. The method of claim 1, wherein no detection labels are associated with the cells, ligand and stimulus.

3. The method of claim 1, wherein the PWVs are detected for five or more minutes.

4. The method of claim 1, wherein the one or more cells are immobilized to the surface of the colorimetric resonant reflectance optical biosensor by one or more specific binding substances.

5. The method of claim 4, wherein the one or more specific binding substances are one or more extracellular matrix ligands.

6. A method of determining if a ligand or stimulus is a not a full agonist comprising:

a) immobilizing or placing one or more cells on a surface of a colorimetric resonant reflectance optical biosensor;

b) applying a ligand or stimulus to the one or more cells;

c) detecting colorimetric resonant reflectance optical peak wavelength values (PWVs) for the one or more cells over time; and

d) comparing the PWVs of step (c) to PWVs over time of a full agonist acting on the same or similar one or more cells of step (a);

wherein, the ligand or stimulus is not a full agonist if the PWVs of the ligand or stimulus over time are smaller in magnitude or later in onset or both than the PWVs over time of the full agonist.

7. The method of claim 6, wherein no detection labels are associated with the cells, ligand and stimulus.

8. The method of claim 6, wherein the PWVs are detected for five or more minutes.

9. The method of claim 6, wherein the one or more cells are immobilized to the surface of the colorimetric resonant reflectance optical biosensor by one or more specific binding substances.

10. The method of claim 9, wherein the one or more specific binding substances are one or more extracellular matrix ligands.

11. A method of determining if a ligand or stimulus is a biased agonist comprising:

a) immobilizing or placing one or more cells on a surface of a grating based waveguide biosensor;

b) applying a ligand or stimulus to the one or more cells;

c) detecting changes in effective refractive indices for the one or more cells over time; and

d) comparing the effective refractive indices of step (c) to effective refractive indices over time of a full agonist acting on the same or similar one or more cells of step (a);

wherein, the ligand or stimulus is a biased agonist if the effective refractive indices of the ligand or stimulus over time are smaller in magnitude or later in onset or both than the effective refractive indices over time of the full agonist.

12. The method of claim 11, wherein no detection labels are associated with the cells, ligand and stimulus.

13. The method of claim 11, wherein the effective refractive indices are detected for five or more minutes.

14. The method of claim 11, wherein the one or more cells are immobilized to the surface of the grating based waveguide biosensor by one or more specific binding substances.

15. The method of claim 14, wherein the one or more specific binding substances are one or more extracellular matrix ligands.

16. A method of determining if a ligand or stimulus is a not a full agonist comprising:

a) immobilizing or placing one or more cells on a surface of a grating based waveguide biosensor;

b) applying a ligand or stimulus to the one or more cells;

c) detecting changes in effective refractive indices for the one or more cells over time; and

d) comparing the effective refractive indices of step (c) to effective refractive indices over time of a full agonist acting on the same or similar one or more cells of step (a);

wherein, the ligand or stimulus is not a full agonist if the effective refractive indices of the ligand or stimulus over time are smaller in magnitude or later in onset or both than the effective refractive indices over time of the full agonist.

17. The method of claim 16, wherein no detection labels are associated with the cells, ligand and stimulus.

18. The method of claim 16, wherein the changes in effective refractive indices are detected for five or more minutes.

19. The method of claim 16, wherein the one or more cells are immobilized to the surface of a grating based waveguide biosensor by one or more specific binding substances.

20. The method of claim 19, wherein the one or more specific binding substances are one or more extracellular matrix ligands.